Skip to main content
Clinical Trials/NL-OMON35884
NL-OMON35884
Completed
Phase 4

The Qure study: Q-fever fatigue syndrome - response to treatment - The Qure study

niversitair Medisch Centrum Sint Radboud0 sites180 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Coxiella burnetii
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
180
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • 1\. Males or non\-pregnant, non\-lactating females who are 18 years or older
  • 2\. Laboratory\-proven acute Q fever in the 3 years before presentation and/or positive serology fitting a past infection with Coxiella burnetii
  • AND being severely fatigued, defined by scoring 35 or higher on the subscale fatigue severity of the CIS;
  • AND being fatigued for at least 6 months;
  • AND disabled because of the fatigue, defined by scoring 450 or higher on the SIP;
  • Subjects must sign a written informed consent form.

Exclusion Criteria

  • 1\. Fulfilling criteria for chronic Q fever;
  • 2\. Acute Q fever in the setting of a prosthetic cardiac valve or aneurysm surgery or stenting necessitating prophylactic use of doxycycline;
  • 3\. Pregnancy or unwillingness to use effective contraceptives during the entire study period;
  • 4\. Imminent death;
  • 5\. Inability to give informed consent;
  • 6\. Allergy or intolerance to doxycycline;
  • 7\. Somatic or psychiatric illness that could explain the chronic fatigue;
  • 8\. Subjects who are currently enrolled on other investigational drug trials or receiving investigational agents;
  • 9\. Receiving antibiotics for more than 4 weeks, potentially active against Coxiella burnetti, for any other reason since Q\-fever diagnosis;
  • 10\. Subjects who are receiving and cannot discontinue barbiturates, phenytoin, or carbamazepine (these drugs may increase the metabolism of doxycycline and therefore reducing half\-life of doxycycline);

Outcomes

Primary Outcomes

Not specified

Similar Trials